V. I. Shirokorad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
V. I. Shirokorad has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- A. A. Khukolenko
Clinical Oncological Dispensary
2 shared publications - A. O. Leonova
Omsk Clinical Oncological Dispensary
2 shared publications - D. V. Dolgikh
Moscow City Oncology Hospital No. 62
2 shared publications - E. I. Kopyltsov
Clinical Oncology Dispensary
2 shared publications - I. A. Sikhvardt
Omsk Clinical Oncological Dispensary
2 shared publications - Oleg V. Leonov
Clinical Oncological Dispensary; Omsk State Medical University
2 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 25 (5) , 137-152
Evaluation of the Results of Intraoperative Elimination of Rectal Wall Integrity Violation after Prostatectomy with the Formation of Fascial Duplication in Patients with Prostate Cancer: A Review of Clinical Practice in Two Russian Institutions
Introduction . An intraoperative complication of prostatectomy is injury to the rectal wall. Purpose of the work is to analyze the intraoperative management of rectal wall injuries occurring during prostatectomy. Materials and Methods. A study conducted involving 36 patients who sustained a rectal wall injury during prostatectomy, divided into two groups. Group I consisted of 30 patients in whom two-layer intestinal suture used. Group II consisted of 6 patients in whom an intestinal suture combined with a fascial duplicature. Results . Patients underwent prostatectomy with lymph node dissection. In Group I, 22 complications (73.3 %) classified Clavien-Dindo grade III were recorded, compared to 0 % in Group II. The use of a fascial duplicature in Group II increase operative time (p = 0.234) or blood loss (p = 0.340). There no significant difference in preoperative length of stay (p = 0.312), while total duration of hospitalization was half as long in Group II compared to Group I (p = 0.005). Following disease progression anticancer treatment required in 46.8 % (n = 14) of patients in Group I and 16.6 % (n = 1) of patients in Group II (p > 0.05). Follow-up, 20 men from Group I remained alive, while 8 deaths recorded. Causes of death malignant neoplasms (62.5 %) and cardiovascular diseases (37.5 %). Prostate cancer cause of death in 50.0 % (n = 4) deceased men. No deaths observed in group II. Conclusion . Fascial duplication demonstrated an absence of postoperative complications, with statistically significant reduction length of hospital stay and an improvement in both early and long-term outcomes.
- 2 November 2026
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 25 (5) , 137-152
Open AccessEvaluation of the Results of Intraoperative Elimination of Rectal Wall Integrity Violation after Prostatectomy with the Formation of Fascial Duplication in Patients with Prostate Cancer: A Review of Clinical Practice in Two Russian Institutions
Introduction . An intraoperative complication of prostatectomy is injury to the rectal wall. Purpose of the work is to analyze the intraoperative management of rectal wall injuries occurring during prostatectomy. Materials and Methods. A study conducted involving 36 patients who sustained a rectal wall injury during prostatectomy, divided into two groups. Group I consisted of 30 patients in whom two-layer intestinal suture used. Group II consisted of 6 patients in whom an intestinal suture combined with a fascial duplicature. Results . Patients underwent prostatectomy with lymph node dissection. In Group I, 22 complications (73.3 %) classified Clavien-Dindo grade III were recorded, compared to 0 % in Group II. The use of a fascial duplicature in Group II increase operative time (p = 0.234) or blood loss (p = 0.340). There no significant difference in preoperative length of stay (p = 0.312), while total duration of hospitalization was half as long in Group II compared to Group I (p = 0.005). Following disease progression anticancer treatment required in 46.8 % (n = 14) of patients in Group I and 16.6 % (n = 1) of patients in Group II (p > 0.05). Follow-up, 20 men from Group I remained alive, while 8 deaths recorded. Causes of death malignant neoplasms (62.5 %) and cardiovascular diseases (37.5 %). Prostate cancer cause of death in 50.0 % (n = 4) deceased men. No deaths observed in group II. Conclusion . Fascial duplication demonstrated an absence of postoperative complications, with statistically significant reduction length of hospital stay and an improvement in both early and long-term outcomes.
- 25 September 2026
- Published by Publishing House ABV Press in Supportive Therapy in Oncology
- Vol. 3 (2-3)
Prognostic factors affecting survival rates of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma
Background. Cytoreductive partial nephrectomy (CPN) for metastatic renal cell carcinoma (mRCC) is currently used rarely, and prognostic factors affecting survival rates for this cytoreductive surgery are undefined. Aim. To determine prognostic factors affecting survival rates in patients with mRCC after CPN in real clinical practice. Materials and methods. The retrospective study included 32 patients who underwent CPN at the Municipal Oncologic Hospital No. 62 in Moscow and the Municipal Oncologic Dispensary in St. Petersburg between 2014 and 2022. Clinical data from medical records were obtained and analyzed retrospectively, all patients underwent clinical, laboratory, and pathomorphological examination. Patients’ survival rates were evaluated using the statistical method of survival analysis with calculation of descriptive characteristics of survival time in the form of a life table and construction of Kaplan–Meier curves. Results. In the present study, clear cell variant of renal cell carcinoma was reported in 84.4 % of patients; poorly differentiated tumors were reported in 21.9 %; synchronous metastases in 21.9 % and multiple metastases 59.4 %. Favorable prognosis according to IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) was reported in 34.4 % of patients. Lung metastases were detected most often (53.1 %); the majority of patients (96.9 %) were treated with systemic therapy with targeted drugs. The length of hospital stay was 3.8 ± 6.2 % days; 30-day mortality was 3.1 %. 3- and 5-year overall survival rates were 74 % and 62 %, respectively. Conclusion. The tactics for CPN in mRCC are currently undefined. Multivariate analysis revealed an independent negative effect of sex (p = 0.041), bone (p = 0.003) and lung (p = 0.022) metastases, and ECOG status (p = 0.03) on overall survival rates.
- 25 September 2026
- Published by Publishing House ABV Press in Supportive Therapy in Oncology
- Vol. 3 (2-3)
Prognostic factors affecting survival rates of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma
Background. Cytoreductive partial nephrectomy (CPN) for metastatic renal cell carcinoma (mRCC) is currently used rarely, and prognostic factors affecting survival rates for this cytoreductive surgery are undefined. Aim. To determine prognostic factors affecting survival rates in patients with mRCC after CPN in real clinical practice. Materials and methods. The retrospective study included 32 patients who underwent CPN at the Municipal Oncologic Hospital No. 62 in Moscow and the Municipal Oncologic Dispensary in St. Petersburg between 2014 and 2022. Clinical data from medical records were obtained and analyzed retrospectively, all patients underwent clinical, laboratory, and pathomorphological examination. Patients’ survival rates were evaluated using the statistical method of survival analysis with calculation of descriptive characteristics of survival time in the form of a life table and construction of Kaplan–Meier curves. Results. In the present study, clear cell variant of renal cell carcinoma was reported in 84.4 % of patients; poorly differentiated tumors were reported in 21.9 %; synchronous metastases in 21.9 % and multiple metastases 59.4 %. Favorable prognosis according to IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) was reported in 34.4 % of patients. Lung metastases were detected most often (53.1 %); the majority of patients (96.9 %) were treated with systemic therapy with targeted drugs. The length of hospital stay was 3.8 ± 6.2 % days; 30-day mortality was 3.1 %. 3- and 5-year overall survival rates were 74 % and 62 %, respectively. Conclusion. The tactics for CPN in mRCC are currently undefined. Multivariate analysis revealed an independent negative effect of sex (p = 0.041), bone (p = 0.003) and lung (p = 0.022) metastases, and ECOG status (p = 0.03) on overall survival rates.
- Open Access
- 11 July 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (3) , 77-85
Intraoperative and perioperative rectal wall integrity disruptions after prostatectomy for prostate cancer in two clinical centers: a review of treatment methods, outcomes, follow-up, and oncologic outcomes
Objective : to analyze clinical data from patients with rectal wall injury after prostatectomy, evaluate long-term surgical and oncologic outcomes, and assess the effectiveness of treatment methods. Material and Methods. A retrospective analysis of 34 patients with prostate cancer with rectal wall injury was conducted. Results. Biochemical recurrence was diagnosed in 16 men (47.1 %) with a median of 19.4 months and a median PsA of 0.8 ng/ml. local recurrence was diagnosed in 3 patients (8.8 %) after 3.9 months, 36.0 months and 80.7 months with PsA values of 0.46 ng/ml, 1.275 ng/ml and 5.24 ng/ml, respectively. Generalization of prostate cancer was confirmed in 10 men (29.4 %) with a median of 50.3 months and a median PsA of 18.7 ng/ml. Hormonal resistance of prostate cancer developed in 4 patients (11.8 %). The median follow-up of patients was 85.1 months. One-year mortality was 2.9 %. three patients were lost to follow-up after 12 months, 1.5 years, and 4 years without progression of malignant neoplasms. ten deaths were confirmed from malignant neoplasms (n=6), circulatory diseases (n=3), and unlawful acts committed against the patient (n=1). at the time of follow-up, 21 patients (67.7 %) were alive, of whom 12 (57.1 %) showed no signs of prostate cancer progression. Conclusion. in case of intraoperative and perioperative disruption of the integrity of the rectal wall after prostatectomy, restoration of the rectal defect or long-term carriage of urinary and/or intestinal stomas, possibly lifelong, does not affect the course of the tumor process and is not a direct cause of a reduction in life expectancy in men.
- 11 July 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (3) , 77-85
Open AccessIntraoperative and perioperative rectal wall integrity disruptions after prostatectomy for prostate cancer in two clinical centers: a review of treatment methods, outcomes, follow-up, and oncologic outcomes
Objective : to analyze clinical data from patients with rectal wall injury after prostatectomy, evaluate long-term surgical and oncologic outcomes, and assess the effectiveness of treatment methods. Material and Methods. A retrospective analysis of 34 patients with prostate cancer with rectal wall injury was conducted. Results. Biochemical recurrence was diagnosed in 16 men (47.1 %) with a median of 19.4 months and a median PsA of 0.8 ng/ml. local recurrence was diagnosed in 3 patients (8.8 %) after 3.9 months, 36.0 months and 80.7 months with PsA values of 0.46 ng/ml, 1.275 ng/ml and 5.24 ng/ml, respectively. Generalization of prostate cancer was confirmed in 10 men (29.4 %) with a median of 50.3 months and a median PsA of 18.7 ng/ml. Hormonal resistance of prostate cancer developed in 4 patients (11.8 %). The median follow-up of patients was 85.1 months. One-year mortality was 2.9 %. three patients were lost to follow-up after 12 months, 1.5 years, and 4 years without progression of malignant neoplasms. ten deaths were confirmed from malignant neoplasms (n=6), circulatory diseases (n=3), and unlawful acts committed against the patient (n=1). at the time of follow-up, 21 patients (67.7 %) were alive, of whom 12 (57.1 %) showed no signs of prostate cancer progression. Conclusion. in case of intraoperative and perioperative disruption of the integrity of the rectal wall after prostatectomy, restoration of the rectal defect or long-term carriage of urinary and/or intestinal stomas, possibly lifelong, does not affect the course of the tumor process and is not a direct cause of a reduction in life expectancy in men.
- Open Access
- 18 December 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (3) , 24-40
Prognosis improvement in elderly patients with metastatic renal cell carcinoma in the era of systemic therapy and factors affecting survival rates
Background. Due to increasing life expectancy, the incidence of metastatic renal cell carcinoma (mRCC) in patients aged ≥75 years is growing. Further studies are needed to determine additional prognostic factors in elderly patients with mRCC and indications for systemic therapy. Aim. To determine the impact of prognostic factors and systemic therapy on survival rates in patients aged ≥75 years and 75 years with mRCC. Materials and methods. A retrospective study included 172 patients with mRCC, including 77 patients aged ≥75 years, who received systemic therapy at the Moscow City Oncology Hospital No. 62 (Moscow) and the City Clinical Oncological Dispensary (Saint Petersburg) between 2006 and 2020. Clinical data from the medical records were obtained and analyzed retrospectively, all patients underwent clinical, laboratory, and pathomorphological examination. Survival rates were evaluated using statistical survival analysis with calculation of descriptive characteristics of lifespans in the form of a life table and construction of Kaplan–Meier curves. Results and conclusion. In the study, elderly patients were less likely to be in the IMDC (International Metastatic RCC Database Consortium) favorable prognosis group (20.8 % vs 29.5 %). In patients ≥75 years of age, solitary metastases (6.5 % vs 15.8 %), liver (7.8 % vs 23.2 %) and lymph node metastases (27.3 % vs 41.1 %) were less frequent, but metastatic bone involvement was more frequently observed (33.8 % vs 26.3 %). In patients ≥75 years of age, metastasectomy was significantly less frequently performed (14.3 % vs 34.7 %). Only liver (p = 0.0066) and lymph node (p = 0.0037) metastases were statistically significantly less frequent in elderly RCC patients, as well as metastasectomy (p = 0.01). The 3- and 5-year overall survival rates in mRCC patients 75 years and ≥75 years were 54.4 % and 35.8 %, 39.7 % and 21.2 % (p = 0.03), respectively. Median overall survival in patients 75 (n = 95) and ≥75 years (n = 77) of age with mRCC was 43.8 months (95 % confidence interval 31.9–52.3) and 32.4 months, respectively (95 % confidence interval 28.9–38.6). Multivariate analysis of patients ≥75 years of age, showed independent negative effect of gender (p 0.001), tumor histologic subtype (p = 0.043), number of metastases (p = 0.049), metastases to bone (p 0.001) and lymph nodes (p = 0.026), IMDC prognosis (p = 0.01), and radiation therapy (p = 0.002) and nephrectomy (p 0.001) on overall survival rates. Multivariate analysis of patients 75 years of age confirmed independent negative effect of tumor histologic subtype (p 0.001) and bone metastases (p = 0.034) on overall survival rates. Older patients with mRCC showed better response to first- and second-line systemic therapy: 57.1 % and 40 %, 65.1 % and 48.5 %, respectively. It is necessary to expand the indications for active treatment in senile mRCC patients in order to increase survival rates.
- 18 December 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (3) , 24-40
Open AccessPrognosis improvement in elderly patients with metastatic renal cell carcinoma in the era of systemic therapy and factors affecting survival rates
Background. Due to increasing life expectancy, the incidence of metastatic renal cell carcinoma (mRCC) in patients aged ≥75 years is growing. Further studies are needed to determine additional prognostic factors in elderly patients with mRCC and indications for systemic therapy. Aim. To determine the impact of prognostic factors and systemic therapy on survival rates in patients aged ≥75 years and 75 years with mRCC. Materials and methods. A retrospective study included 172 patients with mRCC, including 77 patients aged ≥75 years, who received systemic therapy at the Moscow City Oncology Hospital No. 62 (Moscow) and the City Clinical Oncological Dispensary (Saint Petersburg) between 2006 and 2020. Clinical data from the medical records were obtained and analyzed retrospectively, all patients underwent clinical, laboratory, and pathomorphological examination. Survival rates were evaluated using statistical survival analysis with calculation of descriptive characteristics of lifespans in the form of a life table and construction of Kaplan–Meier curves. Results and conclusion. In the study, elderly patients were less likely to be in the IMDC (International Metastatic RCC Database Consortium) favorable prognosis group (20.8 % vs 29.5 %). In patients ≥75 years of age, solitary metastases (6.5 % vs 15.8 %), liver (7.8 % vs 23.2 %) and lymph node metastases (27.3 % vs 41.1 %) were less frequent, but metastatic bone involvement was more frequently observed (33.8 % vs 26.3 %). In patients ≥75 years of age, metastasectomy was significantly less frequently performed (14.3 % vs 34.7 %). Only liver (p = 0.0066) and lymph node (p = 0.0037) metastases were statistically significantly less frequent in elderly RCC patients, as well as metastasectomy (p = 0.01). The 3- and 5-year overall survival rates in mRCC patients 75 years and ≥75 years were 54.4 % and 35.8 %, 39.7 % and 21.2 % (p = 0.03), respectively. Median overall survival in patients 75 (n = 95) and ≥75 years (n = 77) of age with mRCC was 43.8 months (95 % confidence interval 31.9–52.3) and 32.4 months, respectively (95 % confidence interval 28.9–38.6). Multivariate analysis of patients ≥75 years of age, showed independent negative effect of gender (p 0.001), tumor histologic subtype (p = 0.043), number of metastases (p = 0.049), metastases to bone (p 0.001) and lymph nodes (p = 0.026), IMDC prognosis (p = 0.01), and radiation therapy (p = 0.002) and nephrectomy (p 0.001) on overall survival rates. Multivariate analysis of patients 75 years of age confirmed independent negative effect of tumor histologic subtype (p 0.001) and bone metastases (p = 0.034) on overall survival rates. Older patients with mRCC showed better response to first- and second-line systemic therapy: 57.1 % and 40 %, 65.1 % and 48.5 %, respectively. It is necessary to expand the indications for active treatment in senile mRCC patients in order to increase survival rates.